VI 0134
Latest Information Update: 10 Dec 2021
Price :
$50 *
At a glance
- Originator VIVUS
- Class
- Mechanism of Action Serotonin 3 receptor antagonists; Serotonin 4 receptor agonists; Serotonin 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Premature ejaculation
Most Recent Events
- 18 Sep 2006 Discontinued - Phase-II for Premature ejaculation in USA (PO)
- 15 May 2001 VIVUS has been granted a US patent for the use of serotonin-4 receptor agonists and antagonists in the treatment of premature ejaculation
- 23 Mar 2000 VIVUS has been granted a US patent for the use of serotonin-3 receptor antagonists in the treatment of premature ejaculation